Attend Community Conversations with Amylyx Pharmaceuticals
Media Contact: Theresa Garner, [email protected]
I AM ALS celebrates Amylyx Pharmaceuticals’ plan to submit a new drug application (NDA) to the FDA for approval of its AMX0035 treatment in the coming months. The move follows months of sustained advocacy, including more than 50,000 people in the ALS advocacy community signing a petition to make AMX0035 available to people with ALS.
On October 18, 2020, in response to the New England Journal of Medicine publication of encouraging clinical trial results showing that Amylyx Pharmaceuticals’ AMX0035 brought statistically significant benefit to people living with ALS, The ALS Association and I AM ALS immediately called on the drug company and the FDA to make the treatment widely available as soon as possible. Data from the trial (known as CENTAUR), indicates the drug met its pre-specified, primary outcome and represents a significant development for the ALS community.
We will find cures for ALS. The only question is when. That answer depends on you.
Stay informed on I AM ALS’ progress and what you can do to help us make hope real.
I AM ALS Hires Director of Science and Policy
I AM ALS taps Dr. Megan Miller to work with the community in transforming the ALS research ecosystem through patient-driven strategy.
Congressional Hearing Testimony with the FDA
Brian Wallach and Sandra Abrevaya testified before Congress during the House Energy and Commerce Health Subcommittee hearing on "The path forward: advancing treatments and cures for neurodegenerative diseases." This is their full testimony.